Skip to main content
. Author manuscript; available in PMC: 2015 Jul 1.
Published in final edited form as: Pancreas. 2014 Jul;43(5):708–719. doi: 10.1097/MPA.0000000000000109

Figure 6. Effect of the fractalkine receptor (CX3CR1) agonist, fractalkine (CX3CL1), on cell proliferation of PSCs.

Figure 6

Activated PSCs (passages 3 – 5) (2000 cells/well) were pre-incubated for 24 hours in serum free medium and then incubated for 24 hours with the indicated concentrations of CX3CL1 (1–100 ng/ml), MCP-1 (25–100 ng/ml), PDGF-BB (25 ng/ml), or untreated (UT). Growth was determined using a BrdU incorporation assay (A) and the MTS cell viability assay (B) using a coloriometric microplate reader. This figure shows a concentration-dependent effect of CX3CL1 on cell proliferation after 24 hours. ★★=P<0.01, comparing untreated and treated with CX3CL1 or PDGF. These results were the means of four experiments.